Market Overview

Jim Cramer Weighs In On Sage Therapeutics, FireEye And Palo Alto

Benzinga's Daily Biotech Pulse: FDA Nods For Teligent And Keytruda, Sonoma's Q4 Miss, Sage Inks Deal With Japan's Shionogi
10 Biggest Price Target Changes For Wednesday
Institutional Top Ideas: Cormorant Asset Management (Seeking Alpha)
Related FEYE
Cybersecurity Stocks Trade Lower After White House Eliminates Vacant Cyber Coordinator Position
AMD, Aphria, Canopy Growth, FireEye: 'Fast Money' Picks For May 15

On CNBC's "Mad Money", Jim Cramer spoke about SAGE Therapeutics Inc (NASDAQ: SAGE). He said that the company had some bad news on its phase III product. He wouldn't buy the stock and he would exit the position on any upswing.

Palo Alto Networks Inc (NYSE: PANW) had a great quarter and FireEye Inc (NASDAQ: FEYE) does great forensic work, thinks Cramer. His favorite stock in the space is Proofpoint Inc (NASDAQ: PFPT).

Posted-In: CNBC Mad Money Jim CramerMedia


Related Articles (PANW + FEYE)

View Comments and Join the Discussion!